Le Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Le Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Qiyi Chen
Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
3 shared publications Yue Xu
Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine
3 shared publicationsYunkun Liu
Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine
3 shared publicationsBo Yang
Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People's Hospital, Tongji University School of Medicine
2 shared publicationsChen Ye
Department of Functional Intestinal Diseases, General Surgery of Shanghai Tenth People’s Hospital, Tongji University School of Medicine 200072
2 shared publications- Hongliang Tian
Department of Colorectal Disease, Intestinal Microenvironment Treatment Center, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (4) , e0077425
Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients
Fecal microbiota transplantation (FMT) is an emerging therapy for inflammatory bowel disease (IBD), yet its efficacy in patients refractory to conventional treatments and its underlying mechanisms require further elucidation. We studied 37 IBD patients (15 ulcerative colitis [UC], 22 Crohn’s disease [CD]) refractory to conventional therapies and 16 healthy donors. FMT monotherapy from a single donor induced week-4 clinical response in 12 UC and 9 biologic-naïve CD patients, with all responders sustaining remission and most achieving endoscopic remission by week 14. Integrated multi-omics revealed FMT restored microbial diversity and profoundly reorganized host-microbiota-metabolite networks. In nine refractory CD patients (7 infliximab [IFX] non-responders, 2 FMT non-responders), IFX-FMT combination led to week-4 response in 6 patients, all of whom attained clinical and endoscopic remission by week 14, with more complete microbial-metabolic restoration than monotherapy. Our findings establish that FMT induces remission in refractory IBD via ecosystem network rewiring, and that IFX-FMT exhibits additive effects, supporting further trials of microbiome-directed adjunctive strategies. IMPORTANCE: This study provides mechanistic and clinical insights into the therapeutic effects of fecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD), particularly when combined with the anti-tumor necrosis factor (anti-TNF) biologic infliximab (IFX). While both FMT and IFX achieve response in approximately 60% of IBD patients, their combined influence on the gut microbial and metabolic landscape in refractory disease has been poorly understood. Here, we demonstrate that FMT monotherapy restores gut microbial diversity and reconfigures host-microbiota-metabolite networks, correlating with clinical and endoscopic remission in patients refractory to conventional treatments. Furthermore, in Crohn's disease patients unresponsive to either therapy alone, combined IFX-FMT induced more complete microbial and metabolic normalization and achieved remission where monotherapy had failed. These findings reveal ecosystem-level network rewiring as a central mechanism of FMT efficacy and establish the additive potential of combining microbiome-targeted and immunomodulatory therapies. This work supports the development of microbiome-informed adjunctive strategies for severe or refractory IBD, highlighting an actionable path toward personalized, mechanism-based treatment regimens. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT07149441 .
- 21 April 2026
- Published by American Society for Microbiology in mSystems
- Vol. 11 (4) , e0077425
Open AccessAdditive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients
Fecal microbiota transplantation (FMT) is an emerging therapy for inflammatory bowel disease (IBD), yet its efficacy in patients refractory to conventional treatments and its underlying mechanisms require further elucidation. We studied 37 IBD patients (15 ulcerative colitis [UC], 22 Crohn’s disease [CD]) refractory to conventional therapies and 16 healthy donors. FMT monotherapy from a single donor induced week-4 clinical response in 12 UC and 9 biologic-naïve CD patients, with all responders sustaining remission and most achieving endoscopic remission by week 14. Integrated multi-omics revealed FMT restored microbial diversity and profoundly reorganized host-microbiota-metabolite networks. In nine refractory CD patients (7 infliximab [IFX] non-responders, 2 FMT non-responders), IFX-FMT combination led to week-4 response in 6 patients, all of whom attained clinical and endoscopic remission by week 14, with more complete microbial-metabolic restoration than monotherapy. Our findings establish that FMT induces remission in refractory IBD via ecosystem network rewiring, and that IFX-FMT exhibits additive effects, supporting further trials of microbiome-directed adjunctive strategies. IMPORTANCE: This study provides mechanistic and clinical insights into the therapeutic effects of fecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD), particularly when combined with the anti-tumor necrosis factor (anti-TNF) biologic infliximab (IFX). While both FMT and IFX achieve response in approximately 60% of IBD patients, their combined influence on the gut microbial and metabolic landscape in refractory disease has been poorly understood. Here, we demonstrate that FMT monotherapy restores gut microbial diversity and reconfigures host-microbiota-metabolite networks, correlating with clinical and endoscopic remission in patients refractory to conventional treatments. Furthermore, in Crohn's disease patients unresponsive to either therapy alone, combined IFX-FMT induced more complete microbial and metabolic normalization and achieved remission where monotherapy had failed. These findings reveal ecosystem-level network rewiring as a central mechanism of FMT efficacy and establish the additive potential of combining microbiome-targeted and immunomodulatory therapies. This work supports the development of microbiome-informed adjunctive strategies for severe or refractory IBD, highlighting an actionable path toward personalized, mechanism-based treatment regimens. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT07149441 .
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 14, goag024
Changes in bowel-movement frequency, gut microbiota, and emotional issues in postoperative constipation patients
Background: In recent years, the prevalence of chronic constipation among adults worldwide has shown a yearly increasing trend, with most patients experiencing varying degrees of emotional disorders. Understanding the underlying mechanisms linking chronic constipation, gut microbiota, and emotional status is crucial for developing effective therapeutic strategies. Objectives: To investigate the clinical efficacy of surgical intervention for slow-transit constipation and evaluate its postoperative impacts on bowel function, gut microbiota composition and function, and host immune status. Methods: This study aimed to explore the relationship between gut microbiota and emotional status by collecting preoperative and postoperative clinical data, psychological conditions, and gut microbiota profiles from 30 patients undergoing total colectomy with ileorectal anastomosis for chronic constipation. Clinical and microbiota data were analysed to evaluate changes in emotional status and gut microbiota composition before and after surgery. Results: The results demonstrated that the anxiety and depression levels of patients significantly improved following surgery. Concurrently, gut microbiota diversity noticeably decreased, accompanied by significant alterations in species composition. Postoperative changes revealed that Clostridium sensu stricto and Streptococcus were key species contributing to the differences observed between preoperative and postoperative microbiota profiles. Notably, Streptococcus was negatively correlated with emotional symptoms such as obsession, anxiety, and depression, and positively correlated with the lactose and galactose degradation pathway. Conclusions: This study suggests that constipation surgery not only improves bowel movements, but also alters the composition of gut microbiota and ameliorates mood disorders in patients. These findings provide novel insights into the interplay between gut microbiota and emotional well-being, highlighting the potential of targeting gut microbiota as a therapeutic approach for managing psychological conditions associated with chronic constipation.
- 20 January 2026
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 14, goag024
Open AccessChanges in bowel-movement frequency, gut microbiota, and emotional issues in postoperative constipation patients
Background: In recent years, the prevalence of chronic constipation among adults worldwide has shown a yearly increasing trend, with most patients experiencing varying degrees of emotional disorders. Understanding the underlying mechanisms linking chronic constipation, gut microbiota, and emotional status is crucial for developing effective therapeutic strategies. Objectives: To investigate the clinical efficacy of surgical intervention for slow-transit constipation and evaluate its postoperative impacts on bowel function, gut microbiota composition and function, and host immune status. Methods: This study aimed to explore the relationship between gut microbiota and emotional status by collecting preoperative and postoperative clinical data, psychological conditions, and gut microbiota profiles from 30 patients undergoing total colectomy with ileorectal anastomosis for chronic constipation. Clinical and microbiota data were analysed to evaluate changes in emotional status and gut microbiota composition before and after surgery. Results: The results demonstrated that the anxiety and depression levels of patients significantly improved following surgery. Concurrently, gut microbiota diversity noticeably decreased, accompanied by significant alterations in species composition. Postoperative changes revealed that Clostridium sensu stricto and Streptococcus were key species contributing to the differences observed between preoperative and postoperative microbiota profiles. Notably, Streptococcus was negatively correlated with emotional symptoms such as obsession, anxiety, and depression, and positively correlated with the lactose and galactose degradation pathway. Conclusions: This study suggests that constipation surgery not only improves bowel movements, but also alters the composition of gut microbiota and ameliorates mood disorders in patients. These findings provide novel insights into the interplay between gut microbiota and emotional well-being, highlighting the potential of targeting gut microbiota as a therapeutic approach for managing psychological conditions associated with chronic constipation.
- Open Access
- 16 October 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (10) , e0202324
The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation
To investigate the impact of Small Intestinal Bacterial Overgrowth (SIBO) on the efficacy of Fecal Microbiota Transplantation (FMT) in patients with chronic constipation, our research team included 218 patients with chronic constipation treated with FMT. Based on the results of the SIBO breath test, the patients were divided into two groups: the constipation with SIBO group (SIBO) and the constipation without SIBO group (non-SIBO). The efficacy of the two groups was evaluated using constipation-related scoring scales. At the same time, feces and small intestinal fluid samples were collected from both groups before and after FMT to compare the changes in the intestinal microbiota through 16S rRNA sequencing. In this study, it was found that the clinical efficacy of FMT in the SIBO group was superior to that in the non-SIBO group. After FMT treatment, both groups showed a significant increase in bowel frequency and improvement in stool characteristics. Abdominal symptoms, rectal symptoms, and defecation symptoms were significantly alleviated ( P < 0.05), and patients’ quality of life was significantly enhanced ( P < 0.05). After FMT, except for the Constipation Assessment Scale scores, other scale scores showed significant differences between the two groups, the SIBO group scoring significantly better than the non-SIBO group ( P < 0.05). After FMT, there were minor changes in the colonic microbiota but more substantial changes in the small intestinal microbiota. At baseline, the SIBO group had a higher abundance of Veillonella , and lower abundances of Escherichia-Shigella and Acinetobacter compared to the non-SIBO group. Chronic constipation patients with SIBO have a better response to FMT than those without SIBO. IMPORTANCE: Existing studies have rarely considered the impact of the small intestine’s microbial state on the efficacy of fecal microbiota transplantation (FMT), nor have they extensively explored the effect of the small intestine’s microbial state on the recovery of colonic motility. Therefore, this study investigates the influence of small intestinal bacterial overgrowth (SIBO) on the efficacy of FMT in treating constipation, specifically the impact of the microbial state of the small intestine on the restoration of colonic homeostasis, and consequently on the recovery of colonic motility.
- 16 October 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (10) , e0202324
Open AccessThe impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation
To investigate the impact of Small Intestinal Bacterial Overgrowth (SIBO) on the efficacy of Fecal Microbiota Transplantation (FMT) in patients with chronic constipation, our research team included 218 patients with chronic constipation treated with FMT. Based on the results of the SIBO breath test, the patients were divided into two groups: the constipation with SIBO group (SIBO) and the constipation without SIBO group (non-SIBO). The efficacy of the two groups was evaluated using constipation-related scoring scales. At the same time, feces and small intestinal fluid samples were collected from both groups before and after FMT to compare the changes in the intestinal microbiota through 16S rRNA sequencing. In this study, it was found that the clinical efficacy of FMT in the SIBO group was superior to that in the non-SIBO group. After FMT treatment, both groups showed a significant increase in bowel frequency and improvement in stool characteristics. Abdominal symptoms, rectal symptoms, and defecation symptoms were significantly alleviated ( P < 0.05), and patients’ quality of life was significantly enhanced ( P < 0.05). After FMT, except for the Constipation Assessment Scale scores, other scale scores showed significant differences between the two groups, the SIBO group scoring significantly better than the non-SIBO group ( P < 0.05). After FMT, there were minor changes in the colonic microbiota but more substantial changes in the small intestinal microbiota. At baseline, the SIBO group had a higher abundance of Veillonella , and lower abundances of Escherichia-Shigella and Acinetobacter compared to the non-SIBO group. Chronic constipation patients with SIBO have a better response to FMT than those without SIBO. IMPORTANCE: Existing studies have rarely considered the impact of the small intestine’s microbial state on the efficacy of fecal microbiota transplantation (FMT), nor have they extensively explored the effect of the small intestine’s microbial state on the recovery of colonic motility. Therefore, this study investigates the influence of small intestinal bacterial overgrowth (SIBO) on the efficacy of FMT in treating constipation, specifically the impact of the microbial state of the small intestine on the restoration of colonic homeostasis, and consequently on the recovery of colonic motility.